Getting into rehabilitation is part of the treatment.
Cardiac rehabilitation access, walking with arthritis, diabetic foot healing—and a product-specific safety alert.
Radu Physiatry editorial desk · About 11 minutes · AI-assisted, source-checked; not physician-reviewed
A rehabilitation referral is a starting point. The treatment still has to become something a person can attend, tolerate and carry into everyday life. Today’s evidence asks what helps people enter a program, whether limited physical function identifies who responds to a walking intervention, and what a new wound treatment adds to standard care.
The cardiac rehabilitation review was published online October 1. The arthritis analysis appeared September 30; the foot-wound trial belongs to the October 2026 journal issue, with no exact online date established in the abstract record we reviewed. All three were newly found in today’s discovery work. They are abstract-level summaries, paired with established teaching and an October 1 safety notice—not three fully appraised practice recommendations.
Today’s reading lens
Measure the path into treatment as well as the treatment itself.
Enrolment, attendance, daily activity and wound closure answer different questions. A useful result becomes more useful when its population, comparison and uncertainty stay attached.
Cardiopulmonary / October 1, 2026 / systematic review / abstract only
The first hurdle is getting into rehabilitation.
A new review pooled 47 randomized trials involving 10,803 adults eligible for cardiac rehabilitation after conditions or procedures including myocardial infarction, angina, coronary revascularization and heart failure. Strategies varied: education and motivation, different delivery models, invitations and reminders, and peer support. Compared with control, these approaches improved enrolment: relative risk 1.19, 95% confidence interval 1.11–1.29, based on 27 trials and 7,216 participants. Certainty was low. Completion also improved: relative risk 1.22, interval 1.10–1.35, with moderate certainty. Read the original review record.
For patients, the useful conversation is practical: “Am I eligible, who will arrange the program, and which delivery option can I use?” The pooled result does not tell an individual which format will work best.
Clinical notes: process outcomes and evidence certainty
Adherence had a standardized mean difference of 0.32 (95% CI 0.15–0.49; 18 trials, 3,024 participants; moderate certainty). Completion used 19 trials and 5,432 participants. These outcome sets overlap; do not add their sample sizes. Searches ended March 10, 2025. Low-certainty enrolment evidence and varied interventions limit confidence and prevent ranking a particular delivery model. Increased participation here is not a measured reduction in mortality.
Reading boundary: We reviewed the PubMed abstract, not the full review, risk-of-bias tables or individual trials.
A relative gain needs a starting point.
A relative risk of 1.19 means multiplying the baseline probability by 1.19. It does not mean adding 19 percentage points. Illustration only: if 30 of 100 eligible people enrolled under usual care, applying that ratio would give about 36 of 100, roughly six additional people. With a different baseline, the absolute difference changes. These are teaching calculations, not observed local results or a personal prediction.
The American Heart Association describes cardiac rehabilitation as medically supervised exercise training, education about heart health and support for stress reduction. Its patient page was last reviewed April 24, 2024. That is established education, distinct from today’s research update. Explore the AHA explanation.
Rheumatology / September 30, 2026 / secondary trial analysis / abstract only
A lower starting score is not a verdict on someone’s potential.
A secondary analysis examined 267 adults from a randomized trial of telephone-delivered Walk With Ease versus a wait-list control. Researchers asked whether initial chair-stand performance or six-minute walking endurance changed the intervention’s effect on daily steps. Neither interaction was statistically significant: P = 0.27 for chair stands and P = 0.20 for walking endurance. Better baseline function was associated with more steps, but that is a different finding. Read the original analysis.
The high chair-stand subgroup receiving the intervention increased by 731 steps/day at six weeks (95% CI 281–1,182), and 457 at six months (72–843). These are subgroup changes over time, not proof of a treatment-versus-control difference of that size.
Clinical notes: prognostic factor versus treatment-effect modifier
A prognostic association concerns outcomes; an interaction asks whether treatment effects differ across groups. “Significant in one subgroup” does not establish a difference between subgroups. Nor does a nonsignificant interaction prove equal effects. Function was split at sample means, not established clinical cutoffs. Participants averaged 64.2 years; 92% were women. Secondary analysis, categorization and sample size constrain interpretation. The findings do not justify withholding an intervention solely because someone starts with lower function.
Medical complications / October 2026 issue / randomized trial / abstract only
A wound result belongs inside a whole-foot plan.
A multicentre trial randomized 143 people with selected chronic, full-thickness diabetic foot wounds to an ovine forestomach matrix plus hyaluronic acid product and standard care, or standard care alone. In the modified intention-to-treat analysis, 31 of 68 wounds healed by 12 weeks versus 17 of 72: about 46% versus 24%, an absolute difference of roughly 22 percentage points, calculated from the reported counts. The primary comparison had P = 0.008. Read the trial record.
The signal is promising for the selected population. It does not establish which patient should receive the product, the durability of closure, its cost-effectiveness or better community walking.
Clinical notes: inspect who remains in the analysis
The reported analysis includes 140 of 143 randomized participants. The abstract identifies post-randomization exclusions, differential withdrawal and an adjusted comparison near the significance threshold (P = 0.045). Modified intention-to-treat is not automatically equivalent to analyzing everyone as randomized. Missing-outcome handling and adjustment choices require full-text review. “No unexpected safety occurrences” is not proof of no harms.
Reading boundary: Eligibility details, the precise standard-care protocol, funding disclosures and outcome adjudication need full-text appraisal before a treatment recommendation.
Established teaching / IWGDF 2023 guidance / recommendations reviewed
Protect the wound while planning mobility.
Offloading means reducing mechanical stress at the wound. The International Working Group on the Diabetic Foot recommends a non-removable device extending to below the knee as first choice for a neuropathic plantar forefoot or midfoot ulcer, when appropriate. This is a strong recommendation with moderate-certainty evidence. It does not apply identically to every wound. Read the actual guideline, recommendations 1–12.
Clinical notes: location, infection, circulation and balance matter
If a non-removable device is contraindicated or not tolerated, removable knee-high or ankle-high devices are an alternative. Infection and ischaemia alter the pathway; severe infection or ischaemia needs primary attention. Device fitting, stability and fall risk also matter. This is established 2023 guidance, not a new endorsement of the wound product above. An exercise plan and a wound-protection plan must be coordinated by the treating team.
The guideline’s recommendations and relevant rationale were reviewed. Its complete evidence base was not independently reappraised. IWGDF is a supplemental source for this edition, outside the 88-entry discovery registry.
Safety desk / FDA-posted company notice / October 1, 2026
A recall with a specific product, route and lot list.
Greenwich Rx announced a nationwide consumer-level recall of specified lots of compounded glutathione injection because of potentially elevated endotoxin levels. The notice concerns 200 mg/mL in 10 mL multidose vials intended for subcutaneous injection. It reports two patients receiving emergency care after intravenous administration of a product not formulated for that route. Those reports do not quantify the risk for everyone exposed.
The company instructs recipients of recalled lots to stop using them, follow the recall’s disposal instructions and contact their healthcare provider about related health concerns. Check the exact lot list and instructions in the FDA-posted announcement. This is a product-specific safety notice, not a recall of all glutathione products or a finding about rehabilitation efficacy.
Clinical note: product identity includes the route
Medication reconciliation should capture the preparation, concentration, intended route and lot when relevant. FDA posts the company announcement as a public service; that does not endorse the product or company.
What today’s source check can tell you.
Every one of the 88 registered sources was attempted, and all 15 study-domain searches returned indexed results. There were 38 journal-index checks, 38 retrieved landing pages and 12 unavailable sources. All 12 were retried without recovery. The discovery comparison found 121 candidate PMIDs absent from yesterday’s retrieved set; that count is not 121 new treatment advances. Larger searches retrieve only their first 20 candidates. The arthritis paper came from an additional, focused recent-entry search.
The complete registry, access statuses and search boundaries are available in the source desk. Licensed textbook chapters, paid education and linked podcast or video content were not verified by fetching their landing pages. AAPM&R guidance and safety indexes were inspected for leads; this edition does not claim that every linked guideline was appraised or that no other safety update exists.
For clinicians, a daily reading habit complements formal learning. ABPMR’s current continuing-certification overview describes lifelong learning, assessment and improvement in practice. Check your own requirements through its official overview and certification dashboard. This magazine provides neither CME credit nor official examination questions.
One question to study.
Original teaching question: An intervention has an enrolment relative risk of 1.19. A hypothetical usual-care enrolment rate is 30%. Which interpretation is correct?
Enrolment rises to 49%.
Enrolment would be approximately 35.7% if that ratio applies.
Mortality falls by 19%.
Every patient has a 19% chance of benefiting.
Reveal the answer and reasoning
B. 0.30 × 1.19 = 0.357, or 35.7%. The absolute difference is 5.7 percentage points. The review outcome was enrolment, not mortality, and a pooled relative risk is not a personal probability. This illustration assumes the relative effect applies to the hypothetical baseline; it is not a clinic forecast. Source: cardiac rehabilitation utilisation review.
A small glossary for a deeper read.
Relative risk
The probability of an outcome in one group divided by its probability in another.
Percentage points
The arithmetic difference between two percentages: 36% minus 30% is six percentage points.
Confidence interval
A range expressing statistical uncertainty under the analysis model; it does not capture every possible source of bias.
Effect modifier
A characteristic associated with a different treatment effect; this requires comparing effects, rather than separate subgroup significance tests.
Modified intention-to-treat
An analysis that excludes some randomized participants according to study rules. Read the rules and missing-data methods.
Neuropathic plantar ulcer
A wound on the sole of the foot in the setting of nerve dysfunction.
Ischaemia
Inadequate blood supply to tissue.
Endotoxin
A bacterial component that can provoke a harmful inflammatory response.
The three research summaries were checked against primary PubMed abstract records: a systematic review/meta-analysis, a secondary trial analysis and a randomized wound-care trial. They remain abstract-only; full-text clinical appraisal was not completed. The actual IWGDF offloading guideline recommendations and relevant rationale, AHA patient education, ABPMR continuing-certification overview and FDA-posted recall announcement were separately consulted. This is independent education, not accredited CME or an official ABPMR publication.
The discovery window was 2026/09/02–2026/10/02. A journal index check can miss work not yet indexed. A retrieved landing page does not verify every linked publication, paid course, podcast or textbook chapter. Candidate counts are discovery records, not validated practice changes.
Educational, not medical advice. Discuss treatment choices with your clinician. Sources and evidence evolve; each dated edition preserves what was checked for that issue.